Regeneron Pharmaceuticals (REGN)
(Real Time Quote from BATS)
$1,139.28 USD
-7.47 (-0.65%)
Updated Sep 18, 2024 03:42 PM ET
After-Market: $1,140.43 +1.15 (0.10%) 4:06 PM ET
3-Hold of 5 3
C Value F Growth C Momentum F VGM
Company Summary
Tarrytown, NY-based Regeneron is a biotechnology company focused on the discovery, development and commercialization of treatments targeting severe medical conditions. The company’s portfolio boasts of Eylea (for several eye diseases), partnered drug Dupixent (asthma, atopic dermatitis and chronic rhinosinusitis with nasal polyposis), Praluent (heterozygous familial hypercholesterolemia), Kevzara (moderately-to-severely active rheumatoid arthritis), Libtayo (lung cancer), Evkeeza (homozygous familial hypercholesterolemia), Inmazeb (Ebola), Veopoz (CHAPLE disease), Arcalyst and Zaltrap. The company also developed an antibody cocktail for COVID-19, REGEN-COV, which significantly boosted sales in 2021.
Regeneron has a collaboration agreement with Bayer to co-develop and commercialize ...
Company Summary
Tarrytown, NY-based Regeneron is a biotechnology company focused on the discovery, development and commercialization of treatments targeting severe medical conditions. The company’s portfolio boasts of Eylea (for several eye diseases), partnered drug Dupixent (asthma, atopic dermatitis and chronic rhinosinusitis with nasal polyposis), Praluent (heterozygous familial hypercholesterolemia), Kevzara (moderately-to-severely active rheumatoid arthritis), Libtayo (lung cancer), Evkeeza (homozygous familial hypercholesterolemia), Inmazeb (Ebola), Veopoz (CHAPLE disease), Arcalyst and Zaltrap. The company also developed an antibody cocktail for COVID-19, REGEN-COV, which significantly boosted sales in 2021.
Regeneron has a collaboration agreement with Bayer to co-develop and commercialize co-formulated combinations of Eylea and Eylea HD (aflibercept 8 mg). The company has collaborated with Sanofi on the global development and commercialization of Dupixent, Kevzara and itepekimab. In 2019, Regeneron and Alnylam entered into a global, strategic collaboration to discover, develop and commercialize RNA interference ("RNAi") therapeutics for a broad range of diseases by addressing therapeutic disease targets expressed in the eye and central nervous system ("CNS"), in addition to a select number of targets expressed in the liver.
In 2016, Regeneron collaborated with Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for in vivo therapeutic development. The agreement was expanded in 2020 to jointly develop potential products for the treatment of hemophilia A and B. Both companies further expanded the deal to develop additional in vivo CRISPR-based gene editing therapies focused on neurological and muscular diseases.
In April 2024, Regeneron acquired all oncology and autoimmune research and development programs and hired approximately 160 employees from 2seventy bio as part of its newly launched cell medicines business.
Regeneron’s revenues comprise collaboration revenues, net product sales and technology licensing and other revenues. Revenues in 2023 were $13.1 billion, up 8% from 2022. Eylea sales came in at $5.7 billion in the United States.
General Information
Regeneron Pharmaceuticals, Inc
777 OLD SAW MILL RIVER ROAD
TARRYTOWN, NY 10591
Phone: 914-847-7000
Fax: 914-347-2113
Email: invest@regeneron.com
Industry | Medical - Biomedical and Genetics |
Sector | Medical |
Fiscal Year End | December |
Last Reported Quarter | 6/30/2024 |
Exp Earnings Date | 11/7/2024 |
EPS Information
Current Quarter EPS Consensus Estimate | 11.72 |
Current Year EPS Consensus Estimate | 44.86 |
Estimated Long-Term EPS Growth Rate | 7.80 |
Exp Earnings Date | 11/7/2024 |
Price and Volume Information
Zacks Rank | |
Yesterday's Close | 1,146.75 |
52 Week High | 1,211.20 |
52 Week Low | 769.19 |
Beta | 0.12 |
20 Day Moving Average | 391,316.16 |
Target Price Consensus | 1,166.57 |
4 Week | -3.81 |
12 Week | 7.05 |
YTD | 30.57 |
4 Week | -4.45 |
12 Week | 3.91 |
YTD | 10.53 |
Shares Outstanding (millions) | 110.24 |
Market Capitalization (millions) | 126,411.45 |
Short Ratio | NA |
Last Split Date | NA |
Dividend Yield | 0.00% |
Annual Dividend | $0.00 |
Payout Ratio | 0.00 |
Change in Payout Ratio | 0.00 |
Last Dividend Payout / Amount | NA / $0.00 |
Fundamental Ratios
P/E (F1) | 25.56 |
Trailing 12 Months | 25.74 |
PEG Ratio | 3.30 |
vs. Previous Year | 14.90% |
vs. Previous Quarter | 26.73% |
vs. Previous Year | 12.32% |
vs. Previous Quarter | 12.79% |
Price/Book | 4.48 |
Price/Cash Flow | 26.50 |
Price / Sales | 9.37 |
6/30/24 | 16.80 |
3/31/24 | 16.83 |
12/31/23 | 17.61 |
6/30/24 | 13.13 |
3/31/24 | 13.16 |
12/31/23 | 13.76 |
6/30/24 | 5.44 |
3/31/24 | 5.27 |
12/31/23 | 5.69 |
6/30/24 | 4.62 |
3/31/24 | 4.51 |
12/31/23 | 4.94 |
6/30/24 | 33.02 |
3/31/24 | 32.73 |
12/31/23 | 33.03 |
6/30/24 | 32.04 |
3/31/24 | 29.45 |
12/31/23 | 30.14 |
6/30/24 | 34.01 |
3/31/24 | 30.85 |
12/31/23 | 32.01 |
6/30/24 | 255.87 |
3/31/24 | 244.96 |
12/31/23 | 236.63 |
6/30/24 | 0.70 |
3/31/24 | 0.69 |
12/31/23 | 0.72 |
6/30/24 | 0.10 |
3/31/24 | 0.10 |
12/31/23 | 0.10 |
6/30/24 | 8.75 |
3/31/24 | 9.10 |
12/31/23 | 9.43 |